• Home
  • Biotech Pharmaceutical Co., Ltd.

Biotech Pharmaceutical Co., Ltd.

About Biotech Pharmaceutical Co., Ltd.

Founded in 2000, Biotech Pharmaceutical Co., Ltd. (BPL) is China pioneer in innovative biopharmaceuticals (mAbs, therapeutic vaccines). Its 700+ sales force covers all mainland provinces, plus ~100 clinical/regulatory staff. Its self-developed mAb Nimotuzumab (Taixinsheng), approved for nasopharyngeal, head/neck, pancreatic cancer, with ongoing trials in esophageal/gastric cancers, with annual sal...

Read more Show less
Certifications
  • GMP
    GMP
More certifications Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • Country/Region:
    China
  • Founded:
    2000
  • On CPHI since:
    2026
  • Certificates:
    1
  • Employees:
    1000 - 4999
Company types
Pharmaceutical company
Primary activities
Pharmaceutical Company (generic finished products)
Pharmaceutical Company (innovator finished products)
Contact info
Show contact info Hide contact info

Products from Biotech Pharmaceutical Co., Ltd. (3)

  • Apalutamide /ˌeɪpəˈluːtəmaɪd/ Tablets / 阿帕他胺片

    Product Apalutamide /ˌeɪpəˈluːtəmaɪd/ Tablets / 阿帕他胺片

    • Large and fast-growing market – global sales reached 3.574 billion USD, with growth exceeding that of enzalutamide.

    Only the originator (Janssen) is available in China; generic entry is expected to achieve rapid volume uptake.

    Expanding patient pool – prostate cancer incidence is ...
  • Axitinib Tablets / 阿昔替尼片

    Product Axitinib Tablets / 阿昔替尼片

    • Largest-selling drug in the global renal cancer market – global sales reached 978 million USD in 2024, with a 5-year CAGR of 12.7%.

    The only approved first-line targeted-immunotherapy combination in China (with toripalimab), listed as Category IA recommendation in 2024 CSCO guidelines.
    ...
  • Ebidetide Injection (JY09) / 益百得肽注射液

    Product Ebidetide Injection (JY09) / 益百得肽注射液

    1.Has a half-life of up to 240 hours and is the first bi-weekly GLP-1 receptor agonist globally to enter Phase III, significantly improving patient compliance.2.Precisely regulates insulin secretion only when blood glucose is elevated, resulting in an extremely low risk of hypoglycemia.3.Incidence of ...